SPC Financial Inc. Purchases 122 Shares of Gilead Sciences, Inc. $GILD

SPC Financial Inc. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,902 shares of the biopharmaceutical company’s stock after acquiring an additional 122 shares during the quarter. SPC Financial Inc.’s holdings in Gilead Sciences were worth $654,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in GILD. Price T Rowe Associates Inc. MD increased its stake in Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares during the last quarter. Nuveen LLC bought a new position in Gilead Sciences in the first quarter valued at approximately $620,415,000. Kingstone Capital Partners Texas LLC bought a new position in Gilead Sciences in the second quarter valued at approximately $238,083,000. Los Angeles Capital Management LLC increased its stake in Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after acquiring an additional 2,040,261 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after acquiring an additional 1,942,433 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GILD shares. Cantor Fitzgerald lifted their price objective on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday. Rothschild & Co Redburn boosted their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 8th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $118.08.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $117.18 on Monday. The firm has a market cap of $145.40 billion, a PE ratio of 23.34, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The firm’s fifty day moving average is $114.65 and its 200-day moving average is $110.25. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 52 week low of $84.17 and a 52 week high of $121.83.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences’s payout ratio is presently 62.95%.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the transaction, the chief executive officer owned 591,203 shares in the company, valued at $66,013,726.98. The trade was a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares in the company, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 77,000 shares of company stock worth $8,853,430 over the last quarter. Company insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.